Coya Therapeutics (COYA) Operating Expenses (2022 - 2026)

Coya Therapeutics has disclosed Operating Expenses across 5 years of filings, most recently posting $7.3 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 10.83% year-over-year to $7.3 million; the TTM figure through Jun 2026 stood at $31.2 million (up 35.25% YoY), while the FY2025 annual figure was $30.5 million, up 46.61% from the prior year.
• Operating Expenses came in at $7.3 million for Q2 2026 at Coya Therapeutics, down from $7.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $10.0 million in Q4 2025 to a low of $1.7 million in Q1 2022.
• Average Operating Expenses over 5 years is $5.0 million, with a median of $4.3 million recorded in 2023.
• Year-over-year, Operating Expenses decreased 5.57% in 2023 and soared 144.74% in 2025.
• Over 5 years, Operating Expenses stood at $2.0 million in 2022, then jumped by 108.98% to $4.2 million in 2023, then slipped by 2.5% to $4.1 million in 2024, then soared by 144.74% to $10.0 million in 2025, then retreated by 27.03% to $7.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $7.3 million in Q2 2026, $7.9 million in Q1 2026, and $10.0 million in Q4 2025.